Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled Navafenterol in Healthy Japanese Men
NCT03159442Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2017
- Primary completion
- Oct 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of navafenterol in chronic obstructive pulmonary disease (COPD) and asthma (4 arms), sponsored by AstraZeneca. Primary endpoints: Adverse events, Concomitant medication and 7 more. Started Jun 2017; status: completed.
02
Drugs
navafenterol
03
Conditions
chronic obstructive pulmonary disease (COPD)asthma
Beyond the preview
Go deeper on NCT03159442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159442.